Published in N Engl J Med on June 20, 2002
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma | NCT01415765
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A (2004) 9.42
Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol (2004) 9.38
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood (2005) 8.37
Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol (2004) 7.68
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A (2003) 7.57
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood (2011) 7.43
Reliability and reproducibility issues in DNA microarray measurements. Trends Genet (2005) 6.79
Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A (2006) 6.26
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol (2014) 6.10
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med (2003) 6.06
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A (2008) 5.90
Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest (2005) 5.90
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell (2010) 3.37
A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med (2006) 3.37
Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome. Physiol Genomics (2007) 3.37
Covariance-regularized regression and classification for high-dimensional problems. J R Stat Soc Series B Stat Methodol (2009) 3.31
Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol (2010) 3.30
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood (2009) 3.17
Estimating Individualized Treatment Rules Using Outcome Weighted Learning. J Am Stat Assoc (2012) 3.13
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood (2005) 3.12
Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia (2007) 3.06
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A (2012) 3.03
Identifying functional modules in protein-protein interaction networks: an integrated exact approach. Bioinformatics (2008) 3.00
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell (2012) 3.00
Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A (2004) 2.74
Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood (2008) 2.66
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood (2006) 2.63
Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med (2005) 2.56
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol (2008) 2.51
Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol (2013) 2.46
Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood (2009) 2.46
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest (2011) 2.44
The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol (2005) 2.42
Extensions of sparse canonical correlation analysis with applications to genomic data. Stat Appl Genet Mol Biol (2009) 2.42
Variation in gene expression patterns in human gastric cancers. Mol Biol Cell (2003) 2.39
Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood (2008) 2.36
Subclass mapping: identifying common subtypes in independent disease data sets. PLoS One (2007) 2.32
Model-Free Feature Screening for Ultrahigh Dimensional Data. J Am Stat Assoc (2012) 2.30
Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood (2007) 2.28
Identification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med (2009) 2.23
InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood (2010) 2.21
BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol (2004) 2.20
MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell (2012) 2.18
Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood (2008) 2.14
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood (2010) 2.09
Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data. Br J Cancer (2003) 2.08
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood (2009) 2.07
Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci U S A (2007) 2.06
Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia (2007) 2.03
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood (2008) 2.00
Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood (2005) 1.99
Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med (2007) 1.94
Personalized medicine in oncology: the future is now. Nat Rev Drug Discov (2010) 1.91
Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival. Nature (2008) 1.91
Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol (2013) 1.91
Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biol Ther (2009) 1.88
Pathway analysis of primary central nervous system lymphoma. Blood (2008) 1.85
Personalized medicine: new genomics, old lessons. Hum Genet (2011) 1.85
Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol (2009) 1.84
Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J Exp Med (2009) 1.80
Gene expression and angiotropism in primary CNS lymphoma. Blood (2006) 1.79
Allowing for mandatory covariates in boosting estimation of sparse high-dimensional survival models. BMC Bioinformatics (2008) 1.78
DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood (2010) 1.77
An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS One (2008) 1.76
Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin Cancer Res (2014) 1.75
A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood (2009) 1.74
Microarray analysis of human leucocyte subsets: the advantages of positive selection and rapid purification. BMC Genomics (2007) 1.74
Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood (2006) 1.74
Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. J Clin Oncol (2015) 1.73
Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. EMBO Mol Med (2009) 1.73
Whole genome amplification of DNA from laser capture-microdissected tissue for high-throughput single nucleotide polymorphism and short tandem repeat genotyping. Am J Pathol (2004) 1.73
BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood (2007) 1.72
FOXP1: a potential therapeutic target in cancer. Expert Opin Ther Targets (2007) 1.72
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood (2014) 1.71
DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. Leukemia (2008) 1.70
FABIA: factor analysis for bicluster acquisition. Bioinformatics (2010) 1.68
A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. Blood (2012) 1.68
HIV infection and lymphoma. J Clin Pathol (2007) 1.67
IRF4: Immunity. Malignancy! Therapy? Clin Cancer Res (2009) 1.61
Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol Rev (2012) 1.60
Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Blood (2009) 1.59
Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS One (2010) 1.58
Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci U S A (2003) 1.58
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One (2011) 1.57
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood (2008) 1.55
Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer (2010) 1.54
The emerging role of CXCL10 in cancer (Review). Oncol Lett (2011) 1.54
Incorporating pathway information into boosting estimation of high-dimensional risk prediction models. BMC Bioinformatics (2009) 1.52
Toward a clinically feasible gene expression-based subclassification strategy for septic shock: proof of concept. Crit Care Med (2010) 1.51
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood (2015) 1.51
Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet (2013) 1.50
Survival analysis with high-dimensional covariates. Stat Methods Med Res (2009) 1.50
Revised response criteria for malignant lymphoma. J Clin Oncol (2007) 22.19
Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci U S A (2002) 20.48
International network of cancer genome projects. Nature (2010) 20.35
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood (2003) 13.92
Empirical studies assessing the quality of health information for consumers on the world wide web: a systematic review. JAMA (2002) 13.61
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet (2005) 11.40
TREM2 variants in Alzheimer's disease. N Engl J Med (2012) 11.35
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet (2010) 10.97
The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res (2010) 10.97
Stromal gene expression predicts clinical outcome in breast cancer. Nat Med (2008) 10.68
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature (2011) 9.71
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med (2010) 8.74
Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet (2010) 8.74
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol (2006) 8.53
De novo transcriptome assembly with ABySS. Bioinformatics (2009) 8.38
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood (2005) 8.37
A loss-of-function RNA interference screen for molecular targets in cancer. Nature (2006) 8.11
Health related virtual communities and electronic support groups: systematic review of the effects of online peer to peer interactions. BMJ (2004) 7.92
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A (2003) 7.57
Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet (2013) 7.44
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood (2011) 7.43
A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med (2006) 7.42
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34